Shah, Nirav N.
Ahn, Kwang Woo
Litovich, Carlos
Sureda, Anna
Kharfan-Dabaja, Mohamed A. http://orcid.org/0000-0001-7394-5185
Awan, Farrukh T.
Ganguly, Siddhartha
Gergis, Usama
Inwards, David
Karmali, Reem
Lazaryan, Alexsandr
Lekakis, Lazaros
Munshi, Pashna
Nathan, Sunita
Saad, Ayman A.
Solh, Melhem
Steinberg, Amir
Vij, Ravi
Wood, William A.
Fenske, Timothy S.
Smith, Sonali
Hamadani, Mehdi
Article History
Received: 14 August 2019
Revised: 6 November 2019
Accepted: 12 November 2019
First Online: 3 December 2019
Change Date: 29 April 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41408-021-00472-w
Conflict of interest
: Dr. Hamadani reports; Research Support/Funding: Takeda Pharmaceutical Company; Otsuka Pharmaceutical; Spectrum Pharmaceuticals; Astellas Pharma. Research Funding to Institution: Janssen R&D, Celgene Corporation, Merck, MedImmune, Seattle Genetics, and Millennium Pharmaceuticals. Consultancy: MedImmune LLC; Janssen R&D; Incyte Corporation; ADC Therapeutics; Cellerant Therapeutics; Celgene Corporation; Pharmacyclics & DOVA Oncology, Magenta Therapeutics, Omeros. Speaker’s Bureau: Celgene Corporation (Inactive); Sanofi Genzyme. Dr. Shah reports receiving honoraria and/or travel support from Incyte, Celgene, and Lentigen Technology; serving on scientific advisory boards for Kite, Celgene, and Cellectar; receiving institutional research support for clinical trials from BMS and Miltenyi Biotec. None of the authors have any competing interests in the manuscript.